Efficacy and safety of antithrombotic therapy with non-vitamin K antagonist oral anticoagulants after transcatheter aortic valve replacement: a systematic review and meta-analysis

Qing An, Shuwen Su, Yan Tu, Lingfeng Gao, Gaopeng Xian, Yujia Bai, Qiong Zhan, Xingbo Xu, Dingli Xu* and Qingchun Zeng*

Abstract

Objective: A meta-analysis was performed to compare the efficacy and safety of antithrombotic therapy with non-vitamin K antagonist oral anticoagulants (NOACs) versus standard care in patients after successful transcatheter aortic valve replacement (TAVR).

Methods: A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and EMBASE databases and ClinicalTrials.gov website (through 21 October 2020) was performed. Risk ratios (RRs) with 95% confidence intervals (CIs) for all outcomes were calculated using random-effects models.

Results: Twelve studies (two studies were randomized controlled trials) comprising 6943 patients were included (5299 had indications for oral anticoagulation (OAC) and 1644 had none). No significant differences were found between NOACs and the standard care in the incidences of all stroke, a composite endpoint, and major/life-threatening bleeding. NOACs were associated with lower all-cause mortality than vitamin K antagonists (VKAs) in post-TAVR patients with indications for OAC after more than 1 year of follow-up [RR = 0.66; 95% CI, (0.42, 0.96); p = 0.03], whereas NOACs exhibited poor outcomes than antiplatelet therapy (APT) in patients without indications for OAC [RR = 1.66; 95% CI, (1.12, 2.45); p = 0.01]. In the prevention of valve thrombosis, NOACs and VKAs were not significantly different in patients with indications for OAC [RR = 0.66; 95% CI, (0.24, 1.84); p = 0.43], whereas NOACs were better than APT in patients without indications for OAC [RR = 0.19; 95% CI, (0.04, 0.83); p = 0.03].

Conclusions: In patients with indications for OAC, post-TAVR antithrombotic therapy with NOACs was more favorable due to its lower all-cause mortality after more than 1 year of follow-up. In those without indications for OAC, NOACs presented poorer outcomes due to its higher all-cause mortality.

Keywords: APT, meta-analysis, NOACs, TAVR, VKAs

Received: 16 June 2021; revised manuscript accepted: 8 October 2021.

Introduction

In patients with severe symptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) is the standard of care for those who are at moderate to high surgical risk, and on 16 August 2019, the U.S. Food and Drug Administration approved expanding the indication for TAVR to low-risk patients. Thromboembolic complications, such as stroke, systemic embolism, valve thrombosis, and venous thromboembolism, have been reported after
TAVR, and subclinical leaflet thrombosis may be associated with an increased incidence of cerebrovascular disease. Therefore, an optimal antithrombotic regimen after TAVR is urgently needed; however, the recent antithrombotic regimens remain controversial and empirically based. According to current American guidelines, aspirin 75–100 mg daily is reasonable (class of recommendation IIa, level of evidence B-R), whereas treatment with low-dose rivaroxaban (10 mg daily) plus aspirin (75–100 mg) is contraindicated (III, B-R) based on the Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy after Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes (GALILEO) trial in TAVR patients without indications for oral anticoagulation (OAC). In patients with atrial fibrillation (AF) and other indications for OAC (such as venous thromboembolism), vitamin K antagonists (VKAs) therapy with a continuation of aspirin has been considered as standard of care and should be administered on the basis of the patient’s CHA2DS2-VASC score (Supplementary Table 1). Patients with a low bleeding risk may be administered with 3- to 6-month dual antiplatelet therapy (DAPT) with aspirin 75 to 100 mg and clopidogrel 75 mg (IIb, B-NR) or anticoagulation with a VKAs to achieve an international normalized ratio (INR) of 2.5 for at least 3 months after TAVR (IIb, B-NR). European guidelines are slightly different, endorsing DAPT for 3 to 6 months after TAVR (IIa, C) or single-antiplatelet therapy in patients with high bleeding risk (IIb, C). According to European guidelines, non-vitamin K antagonist oral anticoagulants (NOACs) may have more advantages than warfarin, but the sample is too small to draw a definite conclusion.

NOACs have been demonstrated to reduce the incidence of thromboembolism in different clinical settings. However, the need for its routine use to prevent thromboembolic events in post-TAVR patients without indications for OAC is not well documented. Moreover, in those with indications for OAC, whether using NOACs or VKAs as anticoagulants in antithrombotic therapy remains unclear and is actively debated, despite the more favorable efficacy profile of NOACs than VKAs in patients with non-valvular AF. This study aimed to compare the efficacy and safety of antithrombotic therapy with NOACs versus standard care after TAVR and to identify the optimal antithrombotic therapy.

Methods
A systematic review and meta-analysis were carried out under the prespecified protocol (PROSPERO: CRD42020215578) and standards in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. The ethical approval was not applicable because this meta-analysis was not associated with ethics.

Search strategy
PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE databases and ClinicalTrials.gov websites were searched for relevant studies from the conception of the study to 21 October 2020. The reference lists of all included studies were independently screened to search for additional studies that were omitted in the primary search. The full details of the search strategy are presented in Supplementary Table 2.

Study selection
Two investigators (Q.A. and S.S.) selected the studies manually and independently using EndNote X9.3.3 software. Study inclusion was based on the PICOS criteria (participants/disease, intervention/exposure, comparison/control, outcomes/endpoint, and study design): (1) participants/disease, post-TAVR patients both with and without indication for long-term OAC; (2) intervention/exposure, utilized NOACs for antithrombotic therapy; (3) comparison/control, used VKAs or APT without NOACs for antithrombotic therapy; (4) outcomes/endpoint, all-cause mortality as the primary outcome; and (5) study design, randomized controlled trials (RCTs), controlled (nonrandomized) clinical trials (CCTs), and cohort studies. The secondary outcomes were categorized into two parts. One was the efficacy outcome, composed of all stroke, valve thrombosis (reduced leaflet motion (≥50% reduction) or the presence of hypoattenuated leaflet thickening (HALT)), and a composite endpoint that was defined as the composite of death, stroke, or thromboembolic events. The other outcome was the safety outcome, including...
major/life-threatening bleeding. All recorded outcomes were defined according to the Valve Academic Research Consortium-2 (VARC-2) criteria. Studies that were not completed or presented with only an abstract were excluded.

**Data extraction and quality assessment**

Two investigators (Q.A. and S.S.) independently extracted data from the eligible studies using the predesigned data extraction tables in Microsoft Excel, which consisted of study characteristics (first author, publication year, and study design), whether anticoagulant indications exist or not, baseline clinical characteristics (patient demographics, CHA2DS2-VASc score, and HAS-BLED score (Supplementary Table 3)), and data on outcomes of interest (total number, occurrence number, and mean/median follow-up time).

Two investigators (Q.A. and S.S.) independently assessed the methodological quality of the included studies. The quality of the RCTs, CCTs, and cohort studies were assessed according to the Cochrane Collaboration Risk of Bias Tool (ROB), Methodological Index for Non-randomized Studies (MINORS), and Newcastle–Ottawa Scale (NOS), respectively. Any disagreement in all processes mentioned above was resolved by an additional researcher (Q.Z.).

**Data analysis**

The measure of effect for all outcomes was the risk ratio (RR) with 95% confidence intervals (CIs). Data were pooled using the Mantel–Haenszel random-effects model, and statistical significance was set at \( p < 0.05 \). An analysis of patients with and without an indication for long-term OAC was conducted, respectively, due to the difference in risk profiles and the need for antithrombotic drugs between the two cohorts. The heterogeneity between studies was evaluated using Cochran’s \( Q \) test and \( I^2 \) index (\( I^2 \geq 50\% \) indicates heterogeneity and \( p \leq 0.1 \) shows significant difference). Subgroup analysis according to follow-up time (> 1 year) was applied to the pooled outcomes with existing heterogeneity. Only if no less than 10 studies were included could we employ meta-regression and contour-enhanced funnel plots to inspect the source of heterogeneity and possible publication bias. Significant publication bias was further explored using Egger’s test. Sensitivity analysis was used to judge the stability of the ultimate results. When there was high heterogeneity (\( I^2 \geq 50\% \)), cumulative analyses with O’Brien–Fleming sequential monitoring boundaries were supplemented, and the Baujat plot was used to explore the source of heterogeneity. RevMan 5.4.1 was utilized to pool the data, perform subgroup analysis, and assess the quality of the included RCTs. STATA 16.0 was utilized to perform meta-regression, perform sensitivity analysis, and assess publication bias. Trial Sequential Analysis (TSA).jar and R x64 3.6.3 were used to perform cumulative analyses and the Baujat plot.

**Results**

**Selection of studies and evaluation of quality**

The primary search identified 2171 records after excluding duplicates. Subsequently, 45 records were left after excluding 2126 records by carefully reviewing the titles and abstracts according to the PICOS principle. After reading the full text, 33 records were excluded for specific reasons listed in Figure 1. Finally, 12 studies with 6943 patients met the inclusion criteria, which included two RCTs,3,16 one nonrandomized clinical trial,17 and nine cohort studies.18–26

Both RCTs were evaluated as high quality (Figure 2), the CCT had a global ideal score being 19 (> 16) (Supplementary Table 4), and all cohort studies were considered of high quality because of the scores ranging from 6 to 9, with an average of 7.30 (Supplementary Table 5).

**Study characteristics and patients’ baseline characteristics**

Patient characteristics are shown in Supplementary Table 6. The common demographic and baseline characteristics, such as mean age (with an average age of 82 years), body mass index, and the percentages of women, diabetes mellitus, and hypertension were similar between the NOACs and VKAs/APT groups. Coronary artery disease (CAD), previous hemorrhagic or ischemic stroke, previous venous or arterial thromboembolism, permanent pacemaker, and chronic obstructive pulmonary disease (COPD), which may have an important impact on the procedure and prognosis of TAVR; the CHA2DS2-VASc and HAS-BLED
scores that can affect the selection of antithrombotic therapy and the study outcomes; the glomerular filtration rate (GFR) and the percentage of chronic renal failure, which reflect kidney function and are related to the choice of NOACs dose,10 were similar between the two groups. A total of 6943 post-TAVR patients (5299 in 10 studies had indications for OAC; 1644 in two studies did not have indications for OAC) were included in this study. Indeed, GALILEO-4D was a sub-study of the GALILEO trial. After reading protocols and supplementary appendices of the two RCTs, the patients included in the GALILEO were categorized into two: those who participated in the GALILEO-4D and those who did not. Data extraction was performed in two parts. The detailed data of outcomes in the studies are shown in Supplementary Table 7.

NOACs therapy versus standard care (VKAs/APT in patients with/without indications for OAC)

The primary outcome (all-cause mortality). The Mantel-Haenszel random-effects model was used to pool the data of 4006 patients with indications for OAC (1459 who received NOACs versus 2547 who received VKAs) and 1644 patients without indications for OAC (826 who received NOACs versus 818 who received APT) from 10 eligible

Figure 1. Flow chart for selection of eligible studies.
Figure 2. Risk of bias summary and quality evaluation of two randomized controlled trials.

studies. As shown in Figure 3, no significant differences were observed between NOACs and VKAs (RR = 0.85; 95% CI, (0.61, 1.18); p = 0.32); however, NOACs were associated with a higher risk of all-cause mortality than APT (RR = 1.66; 95% CI, (1.12, 2.45); p = 0.01).

Subgroup analysis was performed because of the significantly high heterogeneity (I^2 = 68%, p = 0.002) in studies with indications for OAC, and this study demonstrated that NOACs were associated with a lower risk of all-cause mortality than that in VKAs after more than 1 year of follow-up (RR = 0.64; 95% CI, (0.42, 0.96); p = 0.03; Figure 4).

Cumulative analyses were supplemented with O'Brien–Fleming sequential monitoring boundaries due to the significantly high heterogeneity in a composite endpoint (with indications for OAC; I^2 = 66%, p = 0.02). As shown in Figure 8, the results may be false negative, and more clinical trials are needed.

The safety outcome (major/life-threatening bleeding). The Mantel–Haenszel random-effects model was utilized to analyze the data of 4005 patients with indications for OAC (1459 who received NOACs versus 2546 who received VKAs) and 1644 patients without indications for OAC (826 who received NOACs versus 818 who received APT) from 10 eligible studies. No significant differences were observed between the NOACs therapy and standard care groups (Figure 9).

Discussion
This study indicated that all-cause mortality after the use of NOACs was lower than VKAs in post-TAVR patients with indications for OAC and after more than 1 year of follow-up, whereas it was higher than APT in those without indications for OAC. No significant differences were noted between NOACs and standard care in all stroke, a composite endpoint, and major/life-threatening bleeding.

A contour-enhanced funnel plot was completed to inspect possible publication bias, and significant publication bias was further explored using Egger’s test. As a result, no significant publication bias was observed (p = 0.2949, Figure 6).

The secondary outcomes
The efficacy outcomes. For the efficacy outcomes including all stroke, valve thrombosis, and a composite endpoint, the Mantel–Haenszel random-effects model was utilized to pool the data from nine, four, and seven studies. As shown in Figure 7, no significant differences exist in all efficacy outcomes between NOACs and VKAs in patients with indications for OAC. In patients without indications for OAC, no significant differences exist in all stroke and a composite endpoint between NOACs and APT; however, NOACs exhibited better outcomes than APT in preventing valve thrombosis (RR = 0.19; 95% CI, (0.04, 0.83); p = 0.03).

Cumulative analyses were supplemented with O'Brien–Fleming sequential monitoring boundaries due to the significantly high heterogeneity in a composite endpoint (with indications for OAC; I^2 = 66%, p = 0.02). As shown in Figure 8, the results may be false negative, and more clinical trials are needed.
bleeding. As for valve thrombosis, an equal effect was observed between NOACs and VKAs, whereas NOACs possessed a better protective effect than that in APT.

Patients being considered for TAVR are adults with calcific aortic valve stenosis (CAVS) rather than those with congenital AS, rheumatic valve disease, or isolated aortic regurgitation. CAVS is becoming a growing economic and health burden due to its bleak prognosis in symptomatic patients. No pharmacotherapy has a remarkable effect on holding or delaying the disease, and the precise and specific molecular mechanism of
the pathophysiology underlying CAVS remains insufficient, although growing pharmacological treatment targets have been uncovered, such as the vitamin K-dependent matrix Gla-protein (MGP), which is an effective inhibitor of vascular calcification, and the presence of macrophages. Therefore, aortic valve replacement seems to be the only available treatment option, and TAVR has been widely used. First, stroke was the most dreadful ischemic/embolic cerebrovascular complication after TAVR, which accounts for up to 7% of patients within the first year. The need for antithrombotic therapy has been emphasized because of the stable stroke rate in the past decade. A high thromboembolic burden, such as preexisting/new-onset AF and mechanical movement of debris falling during TAVR, increases the incidence of stroke during or after the procedure. Second, several observational studies have suggested that valve thrombosis may be related to an increased risk of cerebrovascular events and reduced long-term durability of transcatheter heart valves. The pathogenesis of valve thrombosis after TAVR is mainly due to stagnant blood flow, and implantation of the prosthetic aortic valve affects the blood flow.
**Figure 7.** Results of the efficacy outcomes: (a) all stroke, (b) valve thrombosis, and (c) a composite endpoint. CI, confidence intervals; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation.
Figure 8. Cumulative analyses with O’Brien–Fleming sequential monitoring boundaries in a composite endpoint (with indications for OAC)

TSA, Trial Sequential Analysis.

Figure 9. Results of the safety outcome.
CI, confidence intervals; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation.
Moreno et al.\(^{38}\) found that supra-annular transcatheter aortic heart valves were associated with a lower risk of valve thrombosis than intra-annular devices. Therefore, recommendations related to antithrombotic therapy could be different according to the type of valve implanted in the future, especially in patients without indications for OAC (e.g. oral anticoagulation may be added after intra-annular devices implantation). Third, the risk of major/life-threatening bleeding is obviously connected to a poor prognosis.\(^{39}\)

Consistent with the patients’ baseline characteristics in this study, it is well known that CAVS is thought to be a degenerative disease, and the vast majority of post-TAVR patients are elderly.\(^{40}\) The balance between thrombogenesis and bleeding is more complex because of a variety of underlying diseases and medication restrictions in the elderly. All of these demonstrated a remarkable essentiality of optimal antithrombotic therapy for post-TAVR patients, especially for those with indications for OAC.

It is worth noting that although VKAs are widely used to prevent thromboembolic events in post-TAVR patients with indications for OAC, calcification cannot be ignored as a side effect.\(^{28}\) Vitamin K is one of the most essential elements of the body. It is not only involved in blood coagulation but is also associated with various vitamin K-dependent proteins related to anticancer effects, inflammation, bone metabolism, and vascular calcification. For instance, in blood vessels, the formation of hydroxyapatite, the apoptosis of vascular smooth muscle cells (VSMCs), and the transdifferentiation of VSMCs to osteoblasts can be reduced by vitamin K2.\(^{41–44}\) The adverse reaction of VKAs, wherein the use of VKAs demonstrated more vascular/valvular calcification, was confirmed in animal models and humans.\(^{45–48}\)

Many practical inconveniences, such as multiple interactions between food and drug, narrow therapeutic window, and the need for regular monitoring, hinder the use of VKAs, especially in multimorbid patients and the elderly.\(^{22}\) All of the above may be reasons for the lower all-cause mortality of NOACs compared with warfarin after long-term follow-up. Conversely, the control of bleeding, which has been insufficient in NOACs, has made great progress in recent years. Methods included dose adjustment of the agents in patients with renal dysfunction, avoiding the concomitant use of other antithrombotic agents if feasible, the use of nonspecific hemostatic agents, and the use of specific reversing agents, which were significant steps in minimizing bleeding risks with NOACs.\(^{10,49,50}\) Furthermore, based on the noninferiority of NOACs, the latest guideline clearly stated that NOACs are an effective alternative to VKA.\(^{5}\) This study showed that NOACs were more favorable than VKAs in patients with indications for OAC when there were no contraindications.

Consistent with current American guidelines, this study suggested that NOACs are contraindicated in those without indications for OAC despite the advantage of preventing valve thrombosis. However, NOACs or VKAs may be used to resolve the reduced leaflet motion (≥50% reduction).\(^{35}\)

No significant heterogeneity was observed in this study except for all-cause mortality (with indications for OAC and no more than 12 months of follow-up) and a composite endpoint (with indications for OAC). A subgroup analysis of the latter was conducted (Figure 10), but significant heterogeneity still existed. The Baujat plot was used to explore the source of heterogeneity (Figure 11). A study by Butt et al. and Jochheim et al. provided the highest contribution to the overall heterogeneity of the former and the latter, respectively. Therefore, data were pooled again after excluding the study by Butt et al. and Jochheim et al. respectively, as shown in Figure 12, the results were steady, and the heterogeneity was not high.

Given the extremely short follow-up time (3 days), data were pooled again after excluding the study by Yanagisawa et al., with steady results (Figure 13).

Sensitivity analysis and cumulative analyses of all-cause mortality (with indications for OAC and more than 12 months of follow-up) were performed, indicating that recent studies tended to report a lower all-cause mortality of NOACs than that in VKAs after more than 1 year of follow-up (Figures 14). However, this may be a false-positive result (Figures 15). The use of NOACs has become increasingly standardized and reasonable with the updating of research and guidelines, especially the dose adjustments of NOACs in patients with chronic kidney disease.\(^{10}\) The latest study by Kawashima et al. excluded patients with estimated GFRs < 30 mL/min/1.73 m\(^2\) who were not eligible for NOACs and reduced the doses of
rivaroxaban according to creatinine clearance, whereas the study by Kalogeras et al. and Kosmidou et al. did not specialize the renal function of the included patients. All the above may be the source of nonsignificant heterogeneity and the reason why recent studies tend to report a lower all-cause mortality of NOACs. The upcoming clinical trials may show more information.

Upcoming clinical trials, such as the Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis (ATLANTIS) trial, may provide further information. The ATLANTIS study was a multicenter, randomized (1:1), phase IIIb, prospective, open-label, superiority study comparing standard of care (SOC group, 751 patients) and an apixaban-based strategy (anti-Xa group, 749 patients) after successful TAVR with 1-year follow-up (ClinicalTrials.gov NCT 02664649). Randomization was stratified according to indications for OAC. In the experimental arm, patients received apixaban or a reduced dose according to the drug label or when apixaban was combined with antiplatelet therapy.
In the control arm, patients received VKA therapy or combined with antiplatelet therapy if there was an indication for OAC or antiplatelet therapy alone (single or dual) if there was no indication for OAC. The main results were presented at the 2021 annual meeting of the American College of Cardiology. In patients with indications for OAC, no significant differences were found between apixaban and VKAs in the primary and secondary outcomes. However, in patients without indications for OAC, apixaban was associated with a higher incidence of combined endpoint consisting of all-cause mortality, all stroke/TIA, and systemic embolism [apixaban 9.5% versus APT 6.3%].

Figure 12. [a] Analysis of all-cause mortality [with indications for OAC and no more than 12 m follow-up] after excluded the study of Butt et al.; [b] analysis of a composite endpoint [with indications for OAC] after excluded the study of Jochheim et al.

CI, confidence intervals; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation.

Figure 13. Analysis of the valve thrombosis after excluded the study of Yanagisawa et al.

CI, confidence intervals; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation.
Figure 14. Sensitivity analysis of all-cause mortality (with indications for OAC and more than 12 m follow-up). CI, confidence intervals.

Figure 15. Cumulative analyses with O’Brien–Fleming sequential monitoring boundaries in all-cause mortality (with follow-up time more than 12 m). TSA, Trial Sequential Analysis.
HR = 1.56, 95% CI, (1.01, 2.43)]. The risk of death was higher in the apixaban group than that in the APT group (apixaban 5.9% versus APT 3.4%, HR = 1.86, 95% CI, (1.04, 3.34)), which was mainly due to the significantly increased incidence of noncardiovascular death in the apixaban group [apixaban 2.66% versus APT 0.96%, HR = 2.99, 95% CI, (1.07, 8.35)]. As for its sub-study, ATLANTIS 4D-CT, which focused on the prevention of valve thrombosis, no significant difference was observed between apixaban and VKAs in patients with indications for OAC [apixaban 9.5% versus VKAs 5.5%, OR = 1.80, 95% CI, (0.62, 5.25), p = 0.28], whereas apixaban was better than APT in patients without indications for OAC [apixaban 8.7% versus APT 15.9%; OR = 0.51; 95% CI, (0.30, 0.86); p = 0.01]. Professor Jean Philippe Collet, who was one of the core members of this clinical trial, pointed out that the apixaban-based antithrombotic strategy did not show clinical benefits superior to the standard of care in post-TAVR patients with or without indications for OAC, apixaban was comparable to warfarin or antiplatelet therapy in terms of safety outcome (bleeding), and apixaban was associated with a decreased incidence of valve thrombosis compared to APT in those without indications for OAC according to the results of the ATLANTIS study and its sub-study ATLANTIS 4D-CT. It should be noted that the use of apixaban significantly increased the risk of noncardiovascular death compared with APT in post-TAVT patients without indications for OAC. The aforementioned results are consistent with those of this study.

Moreover, the results of the ENVISAGE-TAVI AF (Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients with Atrial Fibrillation) study, which was a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with VKAs in patients with prevalent or incident AF as an indication for OAC after successful TAVR with an 18-month follow-up, have been reported. They concluded that edoxaban was noninferior to VKAs for the incidence of net adverse clinical events, with a higher incidence of major bleeding with edoxaban than that with VKAs. This study was not added to the nine cohort studies because of the heterogeneity caused by the difference between cohort studies and RCTs. However, data of all-cause mortality (with indications for OAC and more than 12 months of follow-up, Figure 16) were recombined after including this RCT, and the results indicated that all-cause mortality after the use of NOACs was lower than VKAs in post-TAVR patients with indications for OAC and for more than 1 year of follow-up [RR = 0.72; 95% CI, (0.53, 0.98); p = 0.04], and the heterogeneity became significant [I² = 58%, p = 0.07]. Finally, more RCTs with more than 1 year of follow-up that compare NOACs with VKAs in post-TAVR patients with indications for OAC are needed.

Limitations
The databases were searched comprehensively and simultaneously to evaluate the efficacy and safety of antithrombotic therapy with NOACs in post-TAVR patients with or without indications for OAC. However, there are still some limitations to this study. First, only two studies were included in the subgroup without indications for OAC. However, there have been some clinical
trials on the way to completion, such as REDOX TAVI (NCT04171726) and ADAPT-TAVR (NCT03284827), which would enrich further studies. Second, none of the studies included in the subgroup with indications for OAC were RCTs. Therefore, an ongoing RCTs, called AVATAR (NCT02735902), is expected to be published to update the present study. Third, there were inconsistencies in the doses and duration of NOACs since some of the studies were anticoagulation therapy alone, whereas the other studies were anticoagulation plus double/single antiplatelet drug therapy. All of these may be confounding factors and therefore influence the outcomes. Fourth, all included studies with indications for OAC focused on AF; therefore, more RCTs and studies focused on the other indications for OAC rather than AF are expected to clarify the optimal antithrombotic regimen after TAVR in patients with different conditions. Finally, most of the included studies focused on the use of rivaroxaban; therefore, further studies are needed to explore the details of different NOACs.

Conclusion
Based on the currently available studies, NOACs as antithrombotic therapy might be a better choice in patients with indications for OAC due to its superiority in reducing all-cause mortality (more than 1 year of follow-up), noninferiority in the other aspects, and the limitations of VKAs, and the standard of care with APT is a better antithrombotic therapy in patients lacking indications for OAC. In the future, RCTs are expected to verify this conclusion and determine the optimal antithrombotic therapy.

Author’s Note
This study has been posted on pre-print servers: https://doi.org/10.21203/rs.3.rs-404977/v1 (doi: 10.21203/rs.3.rs-404977/v1). However, the manuscript we submitted has some revisions in format.

Author contributions
All authors contributed to the conceptualization. Q.A., S.S., and Q.Z. involved in data curation. Formal analysis was done by Q.A., Y.T., L.G., and G.X. Funding acquisition was done by Q.Z. Investigation was done by all authors. Q.A., L.G., and X.X. contributed to the Methodology. Project administration was done by Q.A., S.S., and Q.Z. Resources were managed by Q.Z. and D.X. Software management was done by Q.A., G.X., Y.B., and Q.Z. Supervision was carried out by Q.A., X.X., D.X., and Q.Z. All authors involved in validation. Visualization was carried out by Q.A., S.S., Y.T., and G.X. Q.A., S.S., Y.T., L.G., and G.X. contributed to writing—original draft. Q.A., Y.B., Q.Z., X.X., D.X., and Q.Z. contributed to Writing—review and editing. All authors read and approved the final manuscript to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was partly supported by the Science and Technology Program of Guangzhou (201804010086, 201707020012; Q.Z. & D.X.), the National Natural Science Foundation of China (82070403, 81770386; Q.Z.), the Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR110105001; Q.Z.), and the Youth Science and Technology Innovation Talent of Guangdong TeZhi Plan (grant number 2019TQ05Y136; Q.Z.).

ORCID iDs
Qing An https://orcid.org/0000-0001-8959-2652
Qingchun Zeng https://orcid.org/0000-0001-7665-8237

Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supplemental material
Supplemental material for this article is available online.
References

1. Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2017; 69: 1313–1346.

2. Kaul S. Raising the evidentiary bar for guideline recommendations for TAVR: JACC review topic of the week. J Am Coll Cardiol 2020; 76: 985–991.

3. Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382: 120–129.

4. Kahlert P, Knipp SC, Schlammann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121: 870–878.

5. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 143: e72–e227.

6. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons. Circulation 2019; 140: e125–e151.

7. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739–2791.

8. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace 2021; 23: 1612–1676.

9. Kearon C, Akil EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315–352.

10. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498.

11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed) 2009; 339: b2700.

12. Kappetein AP, Head SJ, Genéreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60: 1438–1454.

13. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed) 2011; 343: d5928.

14. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73: 712–716.

15. Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia. Clin Microbiol Infect 2019; 25: 818–827.

16. De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med 2020; 382: 130–139.

17. Seeger J, Gonska B, Rodewald C et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve implantation compared with vitamin K antagonist [Conference abstract]. J Am Coll Cardiol 2016; 68: B92.

18. Butt JH, Backer O, Olesen JB, et al. Vitamin K antagonists versus direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 2021; 7: 11–19.

19. Geis NA, Kiriakou C, Chorianopoulos E, et al. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol 2018; 107: 799–806.
20. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. *JACC Cardiovasc Interv* 2019; 12: 1566–1576.

21. Kalogerias K, Jabbour RJ, Ruparelia N, et al. Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry [Article]. *J Thromb Thrombolysis* 2020; 50: 82–89.

22. Kawashima H, Watanabe Y, Hioki H, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. *JACC Cardiovasc Interv* 2020; 13: 2587–2597.

23. Kosmidou I, Liu Y, Alu MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. *JACC Cardiovasc Interv* 2019; 12: 1580–1589.

24. Mangner N, Crusius L, Haussig S, et al. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. *Am J Cardiol* 2019; 123: 1134–1141.

25. Tang L, Lesser JR, Schneider LM, et al. Prospective evaluation for hypoattenuated leaflet thickening following transcatheter aortic valve implantation. *Am J Cardiol* 2019; 123: 658–666.

26. Yanagisawa R, Tanaka M, Yashima F, et al. Early and late leaflet thrombosis after transcatheter aortic valve replacement: a multicenter initiative from the OCEAN-TAVI registry. *Circ Cardiovasc Interv* 2019; 12: e007349.

27. Lindman BR, Clavel MA, Mathieu P, et al. Calcific aortic stenosis. *Nat Rev Dis Primers* 2016; 2: 1606.

28. Peeters F, Meex SJR, Dweck MR, et al. Calcific aortic valve stenosis: hard disease in the heart: a biomolecular approach towards diagnosis and treatment. *Eur Heart J* 2018; 39: 2618–2624.

29. Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. *Trends Mol Med* 2013; 19: 217–226.

30. Hutcheson JD, Aikawa E and Merryman WD. Potential drug targets for calcific aortic valve disease. *Nat Rev Cardiol* 2014; 11: 218–231.

31. Vranckx P, Windecker S, Welsh RC, et al. Thrombo-embolic prevention after transcatheter aortic valve implantation. *Eur Heart J* 2017; 38: 3341–3350.

32. Guedeney P, Mehran R, Collet JP, et al. Antithrombotic therapy after transcatheter aortic valve replacement. *Circ Cardiovasc Interv* 2019; 12: e007411.

33. Van Mieghem NM, Schipper ME, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. *Circulation* 2013; 127: 2194–2201.

34. Mangieri A, Montalto C, Poletti E, et al. Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review topic of the week. *J Am Coll Cardiol* 2019; 74: 2088–2101.

35. Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. *Lancet (London, England)* 2017; 389: 2383–2392.

36. Sannino A, Hahn RT, Leipsic J, et al. Meta-analysis of Incidence, predictors and consequences of clinical and subclinical bioprosthetic leaflet thrombosis after transcatheter aortic valve implantation. *Am J Cardiol* 2020; 132: 106–113.

37. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. *N Engl J Med* 2015; 373: 2015–2024.

38. Moreno R, Unverdorben M, Jurado-Román A, et al. The risk of valve thrombosis is higher with intra-annular versus supra-annular transcatheter aortic valve prosthesis. A meta-analysis from randomized controlled trials. *Clin Res Cardiol*. Epub ahead of print 19 February 2021. DOI: 10.1007/s00392-021-01818-x.

39. Piccolo R, Pilgrim T, Franzzone A, et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. *JACC Cardiovasc Interv* 2017; 10: 1436–1446.

40. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. *Lancet (London, England)* 2006; 368: 1005–1011.

41. Villa JKD, Diaz MAN, Pizzolo VR, et al. Effect of vitamin K in bone metabolism and vascular calcification: a review of mechanisms of action.
and evidences. Crit Rev Food Sci Nutr 2017; 57: 3959–3970.

42. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974; 71: 2730–2733.

43. Ivanova D, Zhelev Z, Getsov P, et al. Vitamin K: redox-modulation, prevention of mitochondrial dysfunction and anticancer effect. Redox Biol 2018; 16: 352–358.

44. Ferland G. The discovery of vitamin K and its clinical applications. Ann Nutr Metab 2012; 61: 213–218.

45. Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32: 2555–2562.

46. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104: 3231–3232.

47. Price PA, Faus SA and Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400–1407.

48. Andrews J, Psaltis PJ, Bayturan O, et al. Warfarin use is associated with progressive coronary arterial calcification: insights from serial intravascular ultrasound. JACC Cardiovasc Imaging 2018; 11: 1315–1323.

49. Ruff CT, Giugliano RP and Antman EM. Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents. Circulation 2016; 134: 248–261.

50. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 2017; 377: 431–441.

51. Collet JP, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J 2018; 200: 44–50.

52. Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. Epub ahead of print 28 August 2021. DOI: 10.1056/NEJMoa2111016.